Our Experts will contact you providing a quote,
information and estimated timeframe to
your project needs.
With the aging of society and the prevalence of obesity, the incidence of metabolic diseases is increasing year by year, posing a serious threat to human health. The most common metabolic diseases include obesity, type 2 diabetes caused by insulin resistance, metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis (MASLD/MASH), atherosclerotic cardiovascular disease, and so on.
Mouse models have played a crucial role in unraveling the complexities of metabolic and cardiovascular diseases, illuminating complex signaling pathways, genetic and epigenetic regulatory circuits, and multicellular interactions. The advent of genome editing has ushered in a new era of metabolic research, offering unprecedented possibilities for genetic correction of diseases. Given the escalating prevalence of metabolic disorders, which significantly contribute to the development of cardiovascular diseases alongside other health threats, Cyagen has developed a mouse model platform that is meticulously designed for preclinical drug screening and evaluation research.
Cyagen’s Metabolic Disease and Cardiovascular Disease research team has extensive experience collaborating with international pharmaceutical companies, biotechnology firms, and university research departments. They have established disease models related to obesity and diabetes, hyperuricemia, atherosclerosis, and other metabolic-related diseases. We can provide high-quality and comprehensive in vitro research and development (R&D) and in vivo pharmacological efficacy evaluation services, streamlining your preclinical disease research and new drug development.
Cyagen's mouse model platform for drug screening and evaluation can provide you with a variety of metabolic-related gene-edited models, including Ldlr KO (em), Lep KO, Uox-KO (Prolonged), Atp7b KO, Foxj1 KO, and more, to support new drug development.
Our platform encompasses a diverse array of metabolic models and CRO testing capabilities that aim to advance our comprehension and treatment of metabolic disorders, ultimately addressing the interconnected complexities of cardiovascular diseases and other related pathologies.
| Product Number | Product Name | Strain Background | Application |
|---|---|---|---|
| C001507 | B6J-Apoe KO | C57BL/6JCya | Atherosclerosis, Hypercholesterolemia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) |
| C001067 | APOE | C57BL/6NCya | Atherosclerosis |
| C001291 | B6-db/db | C57BL/6JCya | High Blood Sugar and Obesity |
| C001392 | Ldlr KO (em) | C57BL/6JCya | Familial Hypercholesterolemia |
| C001368 | B6-ob/ob（Lep KO） | C57BL/6JCya | Type 2 Diabetes and Obesity |
| C001232 | Uox KO | C57BL/6JCya | Hyperuricemia |
| C001267 | Atp7b KO | C57BL/6NCya | Copper Metabolism Disorder, Wilson's Disease |
| C001265 | Foxj1 KO | C57BL/6NCya | Primary Ciliary Dyskinesia |
| C001266 | Usp26 KO | C57BL/6NCya | Klinefelter Syndrome |
| C001273 | Fah KO | C57BL/6NCya | Phenylketonuria Type 1 |
| C001383 | Alb-Cre/LSL-hLPA | C57BL/6NCya | Cardiovascular Targets |
| C001421 | B6-hGLP-1R | C57BL/6NCya | Metabolic Targets |
| C001400 | B6J-hANGPTL3 | C57BL/6JCya | Metabolic Targets |
| C001493 | FVB-Abcb1a&Abcb1b DKO (Mdr1a/b KO) | FVB | Diseases Related to Blood-Brain Barrier Permeability |
| C001532 | Serping1 KO | C57BL/6JCya | Hereditary Angioedema(HAE) |
|
C001549 |
C57BL/6NCya |
Research on diet-induced obesity, diabetes, inflammation, fatty liver, and other metabolic diseases; drug development, screening, and preclinical efficacy evaluation for obesity. |
|
| C001553 | B6-RCL-hLPA/Alb-cre/TG(APOB) | C57BL/6NCya | Familial hypercholesterolemia (FH); atherosclerotic cardiovascular disease (ASCVD); other cardiovascular diseases (CVD). |
| C001560 | Pah KO | C57BL/6JCya | Phenylketonuria (PKU) |
| I001220 | B6-hPCSK9/Apoe KO | C57BL/6Cya | Research on PCSK9-targeted drug development; studies on metabolic diseases such as hyperlipidemia, stroke, coronary heart disease, and familial hypercholesterolemia (FH). |
| I001223 | Gla KO | C57BL/6NCya | Fabry Disease (FD) |
We can also generate a custom gene edited model for your research - contact us for a free quote and consultation.
The diet-induced obesity (DIO) model recapitulates metabolic factors implicated in human obesity, which has led to its use in studying the relationship between diet, genes, and other factors in the developmental processes of obesity, diabetes, and related metabolic disorders.
Obesity is a metabolic disorder affected by numerous factors such as diet, environment, genetics, and more - it is often the main cause of many chronic diseases. Animal models are essential tools for further understanding of the pathogenesis of obesity and exploring effective treatment methods. At present, animal models of obesity are mainly divided into four categories: diet-induced obesity, hypothalamic obesity, obesity caused by endocrine disorders, and genetic contributors.
Cyagen can provide you with various obesity mouse models and phenotype analysis services - please contact us for a custom project quote.
Diet-induced obesity (DIO) Model
>> Click
here to learn more about DIO mouse models.
Diabetes mellitus (DM) animal models play an important role in the study of diabetes mellitus and are generally categorized into spontaneous, induced, and genetically engineered models.
Diabetes mellitus (DM), commonly known as diabetes, is a syndrome characterized by chronic hyperglycemia and is caused by genetic, environmental, immune, and other factors. Diabetes has become the third leading chronic disease among the population, following cancer and cardiovascular disease (CVD). The American Diabetes Association (ADA) has divided diabetes into four types: type I diabetes (T1DM), type II diabetes (T2DM), other special diabetes, and gestational diabetes.
Cyagen can provide you with various obesity and diabetes mellitus mouse models alongside phenotype analysis services - please contact us for a custom project quote.
a. Type 2 Diabetes Mellitus (T2DM) Mouse Model
>> Click here to learn more about T2DM mouse models.
b. Type 1 Diabetes Mellitus (T1DM) Mouse Model
>> Click here to learn more about T1DM mouse models.
Animal models play an important role in elucidating the pathophysiological mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and the development of new drugs.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a hepatopathy syndrome affecting both adults and children that is characterized by a range of liver conditions affecting people who consume little to no alcohol, including simple fatty liver, steatohepatitis, fatty liver fibrosis, and cirrhosis. MASLD can progress from simple fatty liver through Metabolic Dysfunction-Associated Steatohepatitis (MASH) to liver fibrosis, and even lead to end-stage liver diseases, such as, liver cirrhosis, hepatocellular carcinoma (HCC), or liver failure.
Preclinical studies require the application of different animal models based on the specific MASLD phenotype being studied. The preclinical animal models of MASLD and MASH can be divided into four categories: diet-induced, drug-induced, genetically modified models, and composite (combined) models.
Cyagen can provide you with various Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) mouse models and phenotype analysis services - please contact us for a custom project quote.
a. Diet-induced Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Mouse
Model
>>
Click here to learn more about Diet-induced MASLD mouse models.
b. Chemically Induced Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Mouse
Model
>> Click here to learn more about Chemically-induced MASLD mouse models.
c. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Mouse Model
(Gene-editing)
>>
Click here to learn more about genetically modified MASLD mouse models.
d. Composite (combined) Model - Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Model
>>
Click here to learn more about composite MASLD mouse models.
Cardiovascular diseases (CVDs) are the leading cause of death across the globe, with Atherosclerosis (AS) serving as the common pathological basis of common cardiovascular and cerebrovascular diseases. Atherosclerosis refers to the thickening and hardening of the arterial wall and narrowing of the vascular lumen, caused by depositions of fat, thrombus, connective tissue, and calcium carbonate in blood vessels. Once these plaques have significantly narrowed or completely blocked the arterial lumen, the tissues and organs which normally receive blood from the artery will develop ischemia or necrosis. The use of animal models of atherosclerosis (AS) is an essential tool to study the occurrence, development, and treatment of cardiovascular diseases. At present, the most common model development techniques include feeding, gavage, injection, mechanical injury, immune injury, and genetic modification.
Cyagen can provide you with various atherosclerosis mouse models and phenotype analysis services - please contact us for a custom project quote.
a. Composite (combined) Model - Atherosclerosis Mouse Model
>>
Click here to learn more.
b. Atherosclerosis Mouse Model (Gene-editing)
>> Click here to learn more.
Pancreatitis, a disease that seriously affects the health and quality of life of people, can be classified as either acute or chronic according to its pathological process. Animal models of pancreatitis have played an important role in studying the pathogenesis of pancreatitis and exploring clinical treatment options. There are many methods for preparing pancreatitis animal models, with the injection of sodium taurocholate into the pancreatic duct being a more commonly used method.
Cyagen can provide you with various pancreatitis mouse models and phenotype analysis services - please contact us for a custom project quote.
a. Acute Pancreatitis Mouse Model
>> Click
here to learn more.
b. Chronic Pancreatitis Mouse Model
>>
Click here to learn more.